Context Therapeutics (CNTX) Non Operating Income (2021 - 2026)

Context Therapeutics has disclosed Non Operating Income across 6 years of filings, most recently posting $143088.0 for Q1 2026.

• Non Operating Income for Q1 2026 came in at $143088.0, up 2256.56% year-over-year; the trailing twelve-month figure through Mar 2026 was $350194.0 (up 3167.57% YoY), and the FY2025 annual result was $200471.0, up 14138.59% from the prior year.
• Non Operating Income came in at $143088.0 for Q1 2026 at Context Therapeutics, up from $96555.0 in the prior quarter.
• In the past five years, Non Operating Income ranged from a high of $143088.0 in Q1 2026 to a low of -$61400.0 in Q4 2023.
• The 5-year median for Non Operating Income is $1532.0 (2022), against an average of $16738.6.
• Across the five-year window, Non Operating Income sank 305775.0% in 2023 and surged 3978.76% in 2025, its largest moves.
• Context Therapeutics' Non Operating Income stood at -$2301.0 in 2022, then plunged by 2568.41% to -$61400.0 in 2023, then soared by 105.66% to $3478.0 in 2024, then jumped by 2676.16% to $96555.0 in 2025, then jumped by 48.19% to $143088.0 in 2026.
• The last three Non Operating Income figures came in at $143088.0 (Q1 2026), $96555.0 (Q4 2025), and $83471.0 (Q3 2025), per Business Quant data.